Primary brain tumours in adults

MJ van den Bent, M Geurts, PJ French, M Smits… - The Lancet, 2023 - thelancet.com
The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

NL Albert, N Galldiks, BM Ellingson… - The Lancet …, 2024 - thelancet.com
Summary Response Assessment in Neuro-Oncology (RANO) response criteria have been
established and were updated in 2023 for MRI-based response evaluation of diffuse …

[HTML][HTML] Mitochondria deregulations in cancer offer several potential targets of therapeutic interventions

C Musicco, A Signorile, V Pesce… - International Journal of …, 2023 - mdpi.com
Mitochondria play a key role in cancer and their involvement is not limited to the production
of ATP only. Mitochondria also produce reactive oxygen species and building blocks to …

[HTML][HTML] Precision oncology: 2023 in review

YR Murciano-Goroff, SP Suehnholz, A Drilon… - Cancer Discovery, 2023 - AACR
This article presents a review of recent major advances in precision oncology and the future
implications of these advances, specifying the iterative progress achieved from the end of …

[HTML][HTML] Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

M Weller, J Felsberg, B Hentschel, D Gramatzki… - Acta …, 2024 - Springer
Prognostic factors and standards of care for astrocytoma, isocitrate dehydrogenase (IDH)-
mutant, CNS WHO grade 4, remain poorly defined. Here we sought to explore disease …

[HTML][HTML] Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas

E Blanco-Carmona, A Narayanan, I Hernandez… - Cell Reports …, 2023 - cell.com
The isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-
mutant gliomas are categorized into oligodendrogliomas and astrocytomas, each with …

The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions

JS Young, RA Morshed, SL Hervey-Jumper… - Neuro …, 2023 - academic.oup.com
After recent updates to the World Health Organization pathological criteria for diagnosing
and grading diffuse gliomas, all major North American and European neuro-oncology …

Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma

A Bhatia, R Moreno, AS Reiner, S Nandakumar… - Clinical Cancer …, 2024 - AACR
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain
tumors characterized by a slow-growing phase over several years followed by a rapid …

Molecular profiling and targeted therapies in gliomas

Y Felistia, PY Wen - Current Neurology and Neuroscience Reports, 2023 - Springer
Abstract Purpose of Review Molecular profiling enables the evaluation of genetic alterations
for the diagnosis and classification of gliomas and the selection of appropriate therapies …

[HTML][HTML] Immunotherapy approaches in isocitrate-dehydrogenase-mutant low-grade glioma

M Gallus, D Kwok, S Lakshmanachetty, A Yamamichi… - Cancers, 2023 - mdpi.com
Simple Summary IDH-mutant low-grade gliomas (LGG) are slow-growing glial cell-derived
tumors of the central nervous system (CNS) that predominantly manifest in young adults and …